BioAlliance Pharma

BioAlliance Pharma (Euronext Paris: BIO) is an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections.To attack the challenge of resistance, the company has multiple product opportunities in two broad proprietary drug delivery systems represented by the Lauriad® adhesive technology and the Transdrug® nanoparticle technology . Together with a New Chemical Entities (NCE) program of molecules being developed as new drugs in oncology and HIV, the company is able to address worldwide markets in the EU, U.S, and Asia.

Contact Details: 59, boulevard du Général Martial Valin, 4th Floor Paris Paris 75015 France Tel: 33 (0) 1 45 58 76 00 Fax: 33 (0) 1 45 58 08 81 Email: bioalliance@bioalliancepharma.com WWW: www.bioalliancepharma.com/

Recent Publications by BioAlliance Pharma:
Oncogene-targeted antisense oligonucleotides for the treatment of Ewing sarcoma. The genetic hallmark of the Ewing sarcoma family of tumours (ESFT) is the...	26th January, 2007	Bioalliance Pharma SA, 59 boulevard de M Valin, Paris 75015, France.	Expert Opin Ther Targets. 2005 Aug;9(4):825-30. DOI Direct Link
In vivo potentialities of EWS-Fli-1 targeted antisense oligonucleotides-nanospheres complexes. The EWS/FLI-1 fusion gene, resulting from a t(11;22) translocation, plays...	27th June, 2006	Bioalliance Pharma SA, Paris 75015, France.	Ann N Y Acad Sci. 2005 Nov;1058:52-61. DOI Direct Link
Physico-chemical characterization of polysaccharide-coated nanoparticles. A series of amphiphilic copolymers (PCL-DEX) made of...	25th January, 2006	UMR CNRS 8612, School of Pharmacy, Chatenay Malabry, France; BioAlliance	J Control Release. 2005 Nov 2;108(1):97-111. Epub 2005 Sep 19. DOI Direct Link
A molecular beacon assay for measuring base excision repair activities. The base excision repair (BER) pathway plays a key role in protecting the...	13th July, 2004	BioAlliance Pharma SA, 59, Bvd du General Martial Valin, 75015 Paris,	Biochem Biophys Res Commun. 2004 Jun 18;319(1):240-6. DOI Direct Link
Therapeutic potentialities of EWS-Fli-1 mRNA-targeted vectorized antisense oligonucleotides. We have used structured antisense oligonucleotides (AON), which are...	25th March, 2004	BioAlliance Pharma, 59, Boulevard du General Martial Valin, 75015 Paris.	Ann N Y Acad Sci. 2003 Dec;1002:72-7.
→View more BioAlliance Pharma research publications.

Press Releases on BioAlliance Pharma:
Strativa's Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA	16th June, 2009	Par Pharmaceutical Companies, Inc.	WOODCLIFF LAKE, N.J., June 16 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX),
Strativa Pharmaceuticals Provides Product Pipeline Update	9th April, 2009	Par Pharmaceutical Companies, Inc.	Files NDA for Ondansetron Orally Dissolving Film Strip BioAlliance to Resubmit Loramyc(R) NDA WOODCLIFF LAKE, N.J., April 9 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary
BioAlliance Pharma Announces Results Demonstrating Styrylquinolines	1st January, 1970	Bioalliance Pharma	BioAlliance Pharma Announces Results Demonstrating Styrylquinolines Targeting HIV Integrase Are Synergistic With Other Antiretroviral Agents Study Suggests That SQLs Could Be Used in

BioNews Results for BioAlliance Pharma:
BioAlliance Pharma ranked as France's fastest growing company in the 2009 Deloitte Technology Fast 50	Bionity.com:  Nov 21 2009 5:26AM Matching: bioalliance pharma
BioAlliance Pharma ranked as France's fastest growing company in the 2009 Deloitte Technology Fast 50(TM)	Individual.com:  Nov 20 2009 1:59PM Matching: bioalliance pharma
BioAlliance Pharma ranked as France's fastest growing company in the 2009 Deloitte Technology Fast 50(TM)	RBC Dain Rauscher:  Nov 19 2009 6:06AM Matching: bioalliance pharma
BioAlliance Pharma Ranked as France's Fastest Growing Company in the 2009 Deloitte Technology Fast 50	Pharma Live:  Nov 19 2009 2:36PM Matching: bioalliance pharma
BioAlliance Pharma ranked as France's fastest growing company in the 2009 Deloitte Technology Fast 50„	Genetic Engineering News:  Nov 19 2009 6:51AM Matching: bioalliance pharma
Promote your company here: BioNewsCast - Press Release Distribution	→View more BioAlliance Pharma news.

BioAlliance Pharma Clinical Trials:
Phase 3 Clinical Study for the Treatment of Cold Sore

BioAlliance Pharma Patents:
US Patent No.	Title
7491505	Method for analyzing tumor aggressivity comprising measurement of polymerized actin
7479497	Use of quinoline derivatives with anti-integrase effect and applications thereof
7064133	Quinoline derivatives process of synthesis and medicaments containing these derivatives
7022832	Oligonucleotides containing an antisense sequence stabilized by a secondary structure, pharmaceutical compositions containing them and method of blocking gene expression using them
6916485	Prolonged release bioadhesive therapeutic systems
→View more BioAlliance Pharma patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 383 times since April 2007, the link to the organisation's website has been followed 48 times

Recent Search Terms used to find this page: Loramyc CNRS Bioalliance | .

Search for more companies in Paris

Search for more companies in Paris

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for BioAlliance Pharma